I'm guessing that perhaps they think either it's going to get harder to keep hiring sales people and growing by the same % each year or that they will have captured the easiest part of the addressable market and they could convert distributed markets into direct sales. But I think that addressaable market is underestimated. Perhaps the best indicator is the number of publications about Novosorb. If revenue grows by 50% in 2025 and 2026 then we'd be at $225m not just $180m in 2026
Ann: Macquarie Australia Conference - Presentation, page-28
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
-0.050(2.02%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.45 | $2.35 | $3.794M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2112 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.42 | 27096 | 4 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |